Market Research Logo

North America Mycoplasma Testing in Clinical Market – Industry Trends and Forecast to 2026

North America Mycoplasma Testing in Clinical Market – Industry Trends and Forecast to 2026

Short Description

By Products (Kits and Reagents, Instruments, Services), Technique (Microbial Culture Techniques/Direct Assay, Polymerase Chain Reaction, ELISA, DNA Staining/Indirect Assay, Enzymatic Methods, Others), Disease Area (Respiratory, Urogenital, Gastrointestinal, Cardiovascular, Musculoskeletal, Others), End User (Diagnostic Laboratories, Hospitals, Others), Country (U.S., Canada, Mexico)

Market Definition:
The mycoplasmas are self-replicating bacteria. The variety of species of mycoplasmas can cause various diseases which are related to genitourinary, respiratory, cardiovascular, musculoskeletal, and gastrointestinal and other diseases such as diseases related to hematopoietic system, cutaneous system related diseases such as Erythema Nodosum, Cutaneous Leukocytoclastic Vasculitis, Stevens - Johnson syndrome. The major disease causing species includes Mycoplasma pneumoniae, M genitalium, U parvum, U urealyticum, M. homini and C. pneumoniae.
These mycoplasma causes number of diseases which have been identified by various kits & reagents and instruments. The kits & reagents used in techniques such as mycoplasma detection assay helps in identifying particular mycoplasma, instruments such as PCR, real-time PCR, reader and others.
North America mycoplasma testing in clinical market is projected to register a healthy CAGR in the forecast period of 2019 to 2026.

Market Segmentation:
North America mycoplasma testing in clinical market is segmented into four notable segments which are products, technique, disease area and end user.
• On the basis of products, the market is segmented into kits and reagents, instruments and services

• On the basis of technique, the market is segmented into polymerase chain reaction, ELISA, DNA staining/ indirect assay, enzymatic methods, microbial culture techniques /direct assay and others

• On the basis of disease area, the market is segmented into urogenital, respiratory, cardiovascular, musculoskeletal, gastrointestinal and others

• On the basis of end user, the market is segmented into hospitals, diagnostic laboratories and others


Market Players

The key market players of North America mycoplasma testing in clinical market are:

• Sartorius AG
• MERCK KGAA
• ELITechGROUP
• AB ANALITICA srl
• GOLD STANDARD DIAGNOSTICS
• OSANG Healthcare
• BioFire Diagnostics
• PromoCell GmbH
• Lonza
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Agilent Technologies, Inc.
• Liofilchem Srl
• ZEAKON Diagnostics
• OPERON
• Bio-Rad Laboratories, Inc.
• Sacace Biotechnologies Srl
• Seegene Inc.
• others


The single user license is non-downloadable and non-printable. Global Site license allows these actions.


1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of North America Mycoplasma Testing In Clinical Market
1.4 Currency And Pricing
1.5 Limitations
1.6 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 North America Mycoplasma Testing In Clinical Market: Geographical Scope
2.3 Years Considered For The Study
2.4 Dbmr Tripod Data Validation Model
2.5 Primary Interviews With Key Opinion Leaders
2.6 Dbmr Market Position Grid
2.7 Dbmr Vendor Share Analysis
2.8 Multivariate Modeling
2.9 Products Lifeline Curve
2.10 Secondary Sources
2.11 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Investment In R&D Activities By Pharmaceutical And Biotechnology Companies
3.1.2 Rising Number Of Diseases
3.1.3 Growing Government Initiatives
3.2 Restraints
3.2.1 High Cost Of Instruments
3.2.2 Stringent Government Regulations
3.3 Opportunities
3.3.1 Availibility Of Number Of Techniques For Detection Of Mycoplasma
3.3.2 Strategic Initiatives By Various Companies
3.4 Challenges
3.4.1 Lack Of Skilled Professionals
3.4.2 Challeneges In The Diagnosis Of Mycoplasma Infection
4 Executive Summary
5 Premium Insights
6 North America Mycoplasma Testing In Clinical Market, By Products
6.1 Overview
6.2 Kits & Reagents
6.3 Instruments
6.4 Services
7 North America Mycoplasma Testing In Clinical Market, By Techniques
7.1 Overview
7.2 Microbial Culture Techniques/Direct Assay
7.3 Polymerase Chain Reaction
7.4 Elisa
7.5 Dna Staining/Indirect Assay
7.6 Enzymatic Methods
7.7 Others
8 North America Mycoplasma Testing In Clinical Market, By Disease Area
8.1 Overview
8.2 Respiratory
8.2.1 By Causative Agent
8.2.1.1 Mycoplasma Pneumoniae
8.2.1.2 Mycoplasma Hominis
8.2.1.3 Ureaplasma Urealyticum
8.2.1.4 Mycoplasma Genitalium
8.2.1.5 Others
8.2.2 By Technique
8.2.2.1 Microbial Culture Techniques/Direct Assay
8.2.2.2 Polymerase Chain Reaction
8.2.2.3 Elisa
8.2.2.4 Dna Staining/Indirect Assay
8.2.2.5 Enzymatic Methods
8.2.2.6 Others
8.3 Urogenital
8.3.1 By Causative Agent
8.3.1.1 Mycoplasma Hominis
8.3.1.2 Ureaplasma Urealyticum
8.3.1.3 Mycoplasma Genitalium
8.3.1.4 Mycoplasma Pneumoniae
8.3.1.5 Others
8.3.2 By Technique
8.3.2.1 Microbial Culture Techniques/Direct Assay
8.3.2.2 Polymerase Chain Reaction
8.3.2.3 Elisa
8.3.2.4 Dna Staining/Indirect Assay
8.3.2.5 Enzymatic Methods
8.3.2.6 Others
8.4 Gastrointestinal
8.4.1 By Causative Agent
8.4.1.1 Mycoplasma Pneumoniae
8.4.1.2 Mycoplasma Hominis
8.4.1.3 Ureaplasma Urealyticum
8.4.1.4 Mycoplasma Genitalium
8.4.1.5 Others
8.4.2 By Technique
8.4.2.1 Microbial Culture Techniques/Direct Assay
8.4.2.2 Polymerase Chain Reaction
8.4.2.3 Elisa
8.4.2.4 Dna Staining/Indirect Assay
8.4.2.5 Enzymatic Methods
8.4.2.6 Others
8.5 Cardiovascular
8.5.1 By Causative Agent
8.5.1.1 Mycoplasma Pneumoniae
8.5.1.2 Mycoplasma Hominis
8.5.1.3 Ureaplasma Urealyticum
8.5.1.4 Mycoplasma Genitalium
8.5.1.5 Others
8.5.2 By Technique
8.5.2.1 Microbial Culture Techniques/Direct Assay
8.5.2.2 Polymerase Chain Reaction
8.5.2.3 Elisa
8.5.2.4 Dna Staining/Indirect Assay
8.5.2.5 Enzymatic Methods
8.5.2.6 Others
8.6 Musculoskeletal
8.6.1 By Causative Agent
8.6.1.1 Mycoplasma Pneumoniae
8.6.1.2 Mycoplasma Hominis
8.6.1.3 Ureaplasma Urealyticum
8.6.1.4 Mycoplasma Genitalium
8.6.1.5 Others
8.6.2 By Technique
8.6.2.1 Microbial Culture Techniques/Direct Assay
8.6.2.2 Polymerase Chain Reaction
8.6.2.3 Elisa
8.6.2.4 Dna Staining/Indirect Assay
8.6.2.5 Enzymatic Methods
8.6.2.6 Others
8.7 Others
8.7.1 By Causative Agent
8.7.1.1 Mycoplasma Pneumoniae
8.7.1.2 Mycoplasma Hominis
8.7.1.3 Ureaplasma Urealyticum
8.7.1.4 Mycoplasma Genitalium
8.7.1.5 Others
8.7.2 By Technique
8.7.2.1 Microbial Culture Techniques/Direct Assay
8.7.2.2 Polymerase Chain Reaction
8.7.2.3 Elisa
8.7.2.4 Dna Staining/Indirect Assay
8.7.2.5 Enzymatic Methods
8.7.2.6 Others
9 North America Mycoplasma Testing In Clinical Market, By End User
9.1 Overview
9.2 Hospitals
9.3 Diagnostic Laboratories
9.4 Others
10 North America Mycoplasma Testing In Clinical Market, By Geography
10.1 North America
10.1.1 U.S.
10.1.2 Canada
10.1.3 Mexico
11 North America Mycoplasma Testing In Clinical Market, Company Landscape
11.1 Company Share Analysis: North America
12 Company Profile
12.1 Bio-rad Laboratories, Inc.
12.1.1 Company Snapshot
12.1.2 Revenue Analysis
12.1.3 Company Share Analysis
12.1.4 Product Portfolio
12.1.5 Recent Developments
12.2 Merck Kgaa
12.2.1 Company Snapshot
12.2.2 Revenue Analysis
12.2.3 Company Share Analysis
12.2.4 Product Portfolio
12.2.5 Recent Development
12.3 Biomérieux Sa
12.3.1 Company Snapshot
12.3.2 Revenue Analysis
12.3.3 Company Share Analysis
12.3.4 Product Portfolio
12.3.5 Recent Developments
12.4 Sartorius Ag
12.4.1 Company Snapshot
12.4.2 Revenue Analysis
12.4.3 Company Share Analysis
12.4.4 Product Portfolio
12.4.5 Recent Developments
12.5 Ab Analitica Srl
12.5.1 Company Snapshot
12.5.2 Product Portfolio
12.5.3 Recent Developments
12.6 Agilent Technologies, Inc.
12.6.1 Company Snapshot
12.6.2 Revenue Analysis
12.6.3 Product Portfolio
12.6.4 Recent Developments
12.7 Elitechgroup
12.7.1 Company Snapshot
12.7.2 Product Portfolio
12.7.3 Recent Developments
12.8 Gold Standard Diagnostics
12.8.1 Company Snapshot
12.8.2 Product Portfolio
12.8.3 Recent Developments
12.9 Liofilchem Srl
12.9.1 Company Snapshot
12.9.2 Product Portfolio
12.9.3 Recent Developments
12.10 Lonza
12.10.1 Company Snapshot
12.10.2 Revenue Analysis
12.10.3 Product Portfolio
12.10.4 Recent Developments
12.11 Operon
12.11.1 Company Snapshot
12.11.2 Product Portfolio
12.11.3 Recent Developments
12.12 Osang Healthcare
12.12.1 Company Snapshot
12.12.2 Product Portfolio
12.12.3 Recent Development
12.13 Promocell Gmbh
12.13.1 Company Snapshot
12.13.2 Product Portfolio
12.13.3 Recent Developments
12.14 F. Hoffmann-la Roche Ltd
12.14.1 Company Snapshot
12.14.2 Reveneue Analysis
12.14.3 Product Portfolio
12.14.4 Recent Developments
12.15 Sacace Biotechnologies Srl
12.15.1 Company Snapshot
12.15.2 Product Portfolio
12.15.3 Recent Development
12.16 Seegene Inc. (2018)
12.16.1 Company Snapshot
12.16.2 Revenue Analysis
12.16.3 Product Portfolio
12.16.4 Recent Developments
12.17 Thermo Fisher Scientific Inc.
12.17.1 Company Snapshot
12.17.2 Revenue Analysis
12.17.3 Product Portfolio
12.17.4 Recent Development
12.18 Zeakon Diagnostics
12.18.1 Company Snapshot
12.18.2 Product Portfolio
12.18.3 Recent Development
13 Swot And Dbmr Analysis
14 Conclusion:
15 Questionnaire
16 Related Reports

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report